Introduction {#sec0001}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has garnered global attention as the causative agent for the coronavirus disease 2019 (COVID19) pandemic and its associated morbidity and mortality worldwide. As of today, approximately 6.9 million confirmed cases of COVID19 have been reported in more than 213 countries and territories with an estimated 53,000 critically ill and 4,02,000 deaths (<https://www.worldometers.info/coronavirus/>). First detected in a cluster of patients with pneumonia of unknown cause in the city of Wuhan, China, in December 2019, within two months the outbreak was declared a public health emergency of international concern by the World Health Organization (WHO). Clinical data suggest that the elderly and people with chronic underlying health issues are more prone to SAR-CoV-2 associated illness and death than young individuals. Currently, there is no specific anti-viral treatment or effective vaccines available for COVID19. The available therapies include non-specific anti-viral, antibiotics to treat bacterial infections and sepsis, and corticosteroids to lower inflammation. However, these measures fail in patients with severe disease, which is characterized by a cytokine storm.

The clinical manifestations of viral infection especially SARS, include mild prodrome of fever and myalgias lasting 3-7 days, during which viral replication occurs. Cough, respiratory symptoms, dyspnea, and hypoxemia are the common appearances during the second week of the illness. Finally, dyspnea may progress to respiratory failure, progressive pneumonia, and ARDS. Interestingly, clinical worsening occurs during the time of decreasing viral load [@bib0001], and in several cases, the cause for the determination seems to be immunopathologic injury rather than direct injury from the virus [@bib0002]. Identifying the SARS-CoV-2 virus receptor recognition mechanism, which regulates its virulence and pathogenesis, holds the key to tackle the COVID19 epidemic [@bib0003]. The pathogenesis of SARS-CoV-2 depends on the recognition and engagement of SARS-CoV receptor angiotensin I converting enzyme 2 receptor (ACE2) as an entry receptor and the serine protease transmembrane protease, serine 2 (TMPRSS2) for S protein priming [@bib0004]. The efficiency of ACE2 usage was found to be a vital factor for SARS-CoV-2 transmissibility [@bib0005]. The ACE2 receptor is extensively distributed on the human cell surface, especially the Alveolar Type II cells (AT2) of the lungs and capillary endothelial cells [@bib0006]. It has been reported that usually over-activated immune system of infected patients kills the virus thereby releasing inflammatory mediators resulting in a cytokine storm, with elevated levels of multiple proinflammatory cytokines that cause edema, persistent pain and pressure in the chest, shortness of breath, acute respiratory distress, secondary bacterial infection and increased mortality [@bib0007]. Interestingly, consistent absence of ACE2 in immune cells such as T and B-lymphocytes, and macrophages in bone marrow, lymph nodes, thymus, and spleen [@bib0008], suggests that immunological therapy could be a potential therapeutic option for infected patients.

Considering the seriousness of this deadly pandemic and its impact on the global economy there is an urgent need to develop effective therapies against COVID19. Herein, we proposed Mesenchymal Stem Cells (MSCs) as a possible therapeutic candidate against the SARS-CoV-2 infection. MSCs are an attractive approach for treating both acute and chronic lung pathological conditions like COVID19, mainly because these cells offer multiple protective mechanisms to defend and repair pulmonary damage. Further, MSCs exhibit broad immune regulatory function, which makes them suitable for anti-viral therapy as safety and effectiveness of these cells have been documented in clinical trials of severe lung infections \[[@bib0009],[@bib0010],[@bib0011]\]. Results of preliminary investigations on SARS-CoV-2 infected patients treated with MSCs have revealed a noteworthy reversal of pathological symptoms, further indicating the potential of MSCs in lung infection \[[@bib0007],[@bib0012]\].

MSCs and COVID19 patients {#sec0002}
=========================

To date, one clinical case study and a single center open-label pilot investigation have been reported on COVID19 patients employing MSCs as a therapy \[[@bib0007],[@bib0012]\]. Apart from the above-published preliminary studies, forty-one clinical trials that employ MSC-based therapies have been approved (including seven withdrawn) and are summarized in [Table 1](#tbl0001){ref-type="table"} . Results from these trails are expected to shed light on the pathophysiology of the disease, and the interventions offered by MSCs post-treatment. Here, briefly, we have summarized the outcome of the two papers published from China.Table 1Summary of MSCs based Clinical Trials recorded till April 21^st^ 2020.Table 1S.No.Clinical trial numberStudy TitlePhaseStatusSample Size(n)Cellular InterventionsPrimary Outcome MeasuresLocationsReferences1-NCT04315987Nest Cell ®Mesenchymal Stem Cell to Treat Patients with Severe COVID19 PneumoniaINot Recruiting66Nest Cell ®- Change in Clinical ConditionSao Paulo, Brazil<https://clinicaltrials.gov/ct2/show/NCT04315987?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=12-NCT04313322Treatment of COVID19 Patients Using Wharton\'s Jelly- Mesenchymal Stem CellsIRecruiting5Wharton\'s\
Jelly Mesenchymal Stem Cells- Clinical outcome\
- CT scan\
- RT-PCRStem Cells Arabia,\
Amman,\
Jordan<https://clinicaltrials.gov/ct2/show/NCT04313322?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=23-NCT04288102Treatment With Mesenchymal Stem Cells for Severe Corona Virus Diseases 2019 (COVID19)IIRecruiting90Mesenchymal Stem Cells- Size of lesion area and severity of pulmonary fibrosisMaternal and Child Hospital of Hubei Province,\
Wuhan, Hubei, China and Wuhan Huoshenshan Hospital Wuhan, Hubei, China<https://clinicaltrials.gov/ct2/show/NCT04288102?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=34-NCT04302519Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem CellsEarly phaseINot Recruiting24Dental Pulp Mesenchymal Stem Cells- Disppear time of ground-glass shadow in the lungs-<https://clinicaltrials.gov/ct2/show/NCT04302519?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=45-NCT04252118Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel CoronavirusIRecruiting20Mesenchymal Stem Cells- Size of lesion area\
-Side effects in the MSCs treatment groupBeijing 302 Military Hospital of China,\
Beijing, China<https://clinicaltrials.gov/ct2/show/NCT04252118?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=56-NCT04273646Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia-Not Recruiting48Umbilical Cord Mesenchymal Stem Cells- Pneumonia severity index - Oxygenation index (PaO~2~/FiO~2~)Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,\
Wuhan, Hubei, China<https://clinicaltrials.gov/ct2/show/NCT04273646?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=67-NCT04269525Umbilical Cord (UC)-Derived Mesenchymal Stem Cells (MSCs) Treatment for the 2019-novel Coronavirus (nCOV) PneumoniaIIRecruiting10Umbilical Cord Mesenchymal Stem Cells- Oxygenation indexZhongnan Hospital of Wuhan University,\
Wuhan, Hubei, China<https://clinicaltrials.gov/ct2/show/NCT04269525?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=88-NCT04333368Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDSI and IINot Recruiting60Umbilical Cord Wharton\'s Jelly-derived human- Respiratory efficacyHopital Pitie-Salpetriere - APHP\
Paris, France and Hopital European Georges Pompidou - APHP\
Paris, France<https://clinicaltrials.gov/ct2/show/NCT04333368?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=99-NCT04276987A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus PneumoniaINot Recruiting30Mesenchymal Stem Cells derived exosomes- Adverse reaction (AE) and severe adverse reaction (SAE)\
- Time to clinical improvement-<https://clinicaltrials.gov/ct2/show/NCT04276987?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=1110-NCT04299152Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2IINot Recruiting20Stem Cell Educator-Treated Mononuclear Cells Apheresis- Determi- nation of no.Covid19 patients who were unable to complete SCE therapy.-<https://clinicaltrials.gov/ct2/show/NCT04299152?term=mesenchymal>±stem±cell&cond=COVID19&draw=2&rank=1011-\
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- Frequency of serious adverse eventsChaoyang District, Beijing, China<http://www.chictr.org.cn/showprojen.aspx?proj=50263>31-ChiCTR2000031139Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID19)0Recruiting20The cell dose was 3\*10\^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.- Pulmonary function evaluation\
- Changes in blood gas analysis\
- Evaluation of activity\
- Evaluation of dyspneaDongxihu District, Wuhan, Hubei, China<http://www.chictr.org.cn/showprojen.aspx?proj=51404>32-ChiCTR2000030944Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID19)INot Recruiting20On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased- Changes of serum inflammatory factors\
- Patient death risk\
- Drug related adverse reactions and eventsJiangxi,\
China<http://www.chictr.org.cn/showprojen.aspx?proj=50199>33-ChiCTR2000030866Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID19)0Recruiting30Mesenchymal Stem Cells- Oxygenation index\
- Conversion rate from serious to critical patients\
- Conversion rate and conversion time from critical to serious patients\
- Mortality in serious and critical patientsHu\'nan, China<http://www.chictr.org.cn/showprojen.aspx?proj=50299>34-ChiCTR2000030835Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID19)-Recruiting20Routine treatment + MSc (2 × 10\^6 / kg / time)-He\'nan, China<http://www.chictr.org.cn/showprojen.aspx?proj=51050>[^1][^2][^3][^4][^5][^6][^7][^8]

The first study was a case report [@bib0012], in which a critically ill 65-year-old female with severe pneumonia, respiratory failure, moderate anemia, hypertension, and multiple organ failure received three infusions of umbilical cord MSCs (UCMSCs, 5 × 10^7^ cells/infusion), three days apart. Before receiving UCMSCs, the clinical laboratory examination showed an abnormal percentage of white blood cells, neutrophils and lymphocytes in peripheral blood and the patient received antiviral therapy. During cell therapy, antibiotic was given to manage the bacterial infection, and to modulate the immune system thymosin α1 was injected. Twenty-four hours after the second UCMSCs administration, serum bilirubin, CRP, (AST)/(ALT) and other vital signs began to get stabilized and therefore, the patient no longer required mechanical ventilation. After receiving the second cell infusion, the white blood cell, neutrophil and lymphocyte counts together with T subsets returned to normal levels. Two days after the third injection the patient tested negative for SARS-CoV-2. Consecutive CT scanning pre and post cell administration revealed that pneumonia had resolved. Further, from the first day of UCMSCs infusion till the third day no side effects were observed, signifying the cells were well tolerated.

Another study by Leng et al., 2020 reported that the intravenous administration of clinical-grade human MSCs in SARS-CoV-2 infected patients resulted in improved clinical outcomes [@bib0007]. In this study seven patients (one critically severe, four severe, and two having common symptoms of pneumonia) were enrolled in the treatment group and three patients served as placebo controls (all displaying severe symptoms). All treated patients received a single dose of 1 × 10^6^ MSCs/kg body weight and remarkably all seven showed improvement over a period of two weeks with no noticeable adverse effect. However, within the control group, just one showed improvement, one exhibited ARDS symptoms, and the other died. The overall improvement in the MSCs infused group was striking as within 2 days after treatment pulmonary functions and symptoms of all the seven patients significantly improved, and most tested negative for the SARS-CoV-2 nucleic acid test over two weeks after MSCs infusion. After 6 days of treatment, the cellular immune response showed an elevated peripheral lymphocyte count, decline in C-reactive protein, and the disappearance of activated CXCR3^+^CD4^+^ T cells, CXCR3^+^CD8^+^ T cells, and CXCR3^+^natural killer cells (NK cells). As expected, the number of CD14^+^CD11c^+^CD11b^mid^ regulatory DC cells also returned to normal, levels of the pro-inflammatory cytokine TNF-α was decreased, and the ratio of chemokine IL-10 increased significantly in the MSCs treatment group compared to the placebo control group. Furthermore, the gene expression profile showed that MSCs did not express ACE2 and TMPRSS2 indicating they were free from COVID-19 infection. Finally, the RNA sequencing and gene expression analysis showed that MSCs were closely involved in the anti-viral pathways, and had anti-inflammatory trophic activities [@bib0007]. While both of the above studies have provided new insights into the protective mechanism of MSCs during viral infection, a few shortcomings in these treatments, however, could be noticed. For example, severity and mortality largely correspond to age, and therefore it looks curious to have old patients in the placebo group in the study by Leng et al. Further, there is a lack of information on MSCs processing and screening before infusion, and also the long-term follow-up of patients is missing in both of the above-cited studies. For a protocol to be implicated in a larger cohort, optimal information regarding MSCs as well as patients needs to be investigated in a rationally designed controlled setting.

SARS-CoV-2 infection and Immune response {#sec0003}
========================================

To understand lung pathophysiology associated with SARS-CoV-2 infection it is important to recognize the behavior of the virus within the host (humans). Clinically, the immune reaction induced by SARS-CoV-2 infection has two-stages: i) the immune protective phase (Incubation phase) and ii) Inflammation-driven damage phase (Severe phase) [@bib0013]. During non-severe stages, a particular adaptive immune response is required to remove the virus and to prevent disease progression to severe stages. However, when a protective immune response is impaired, the virus will spread, thus, enormous destruction of not just lung but all ACE2 expressing tissues is imminent. The damaged cells will induce innate inflammation that is largely mediated by pro-inflammatory macrophages and granulocytes [@bib0013]. As MSCs can immunomodulate cells from both the innate and adaptive immune systems \[[@bib0014],[@bib0015],[@bib0016],[@bib0017]\], MSCs could offer a new therapeutic approach to COVID19 patients. However, a major concern is when to initiate MSCs treatment. An argument can be made for stratifying patients based on disease severity and focusing specifically on those that present with a cytokine storm and require ventilation [@bib0018]. Interestingly, in a recent study, displaying results from the responder vs. non-responder towards MSC treatment in GvHD, based on the results obtained, the authors argued that the severity of the disease could help stratify the patients for MSC treatment [@bib0019]. Anyhow, the existing pre-clinical data [@bib0020] and that from clinical trials in non-viral ARDS patients support the use of MSCs in moderate or mild disease although this remains disputable [@bib0021]. However, because of the limited understanding of the pathogenesis of COVID-19, an optimal approach for administration of MSC-based therapies has yet to be established.

Cytokine Storm {#sec0004}
==============

The cytokine storm is a systematic inflammatory response associated with a variety of infectious \[[@bib0022],[@bib0023]\] and non-infectious diseases \[[@bib0024],[@bib0025]\]. This exuberant immune response is clinically related to excessive inflammatory parameters and widespread lung damage, resulting in acute respiratory distress and multi-organ failure \[[@bib0022],[@bib0023]\]. Reports from SARS-CoV-2 infected individuals with critical illness have depicted a complex picture of cytokine networks and their contributions to pathological outcomes [@bib0026] \[[Fig. 1](#fig0001){ref-type="fig"} \]. Thus, preventing and reversing the cytokine storm may be a primary factor in determining the outcome of patients with severe COVID-19 pneumonia. However, very limited information regarding cytokine storm is available in coronavirus studies and existing knowledge of the mechanism underlying the cytokine storm is predicated on the pre-clinical data in influenza infection models \[[@bib0027],[@bib0028]\]. It has been suggested that when a virus infects the epithelial, endothelial and alveolar macrophage, the immune system initiates a rapid anti-viral response for virus clearance and tissue homeostasis. In the process of virus clearance, the immune system activates the signaling cascade resulting in production of several cytokines. The number of cytokines that are produced by direct contact of the virus and immune effector cells is estimated to be greater than 15, without considering chemokines [@bib0029]. The activated cytokines can stimulate the expression of the secondary wave of cytokines. For instance, influenza viral infection in epithelial cells activates type I interferons that upregulate the expression of a variety of interferon-stimulated genes (ISGs) [@bib0030]. In turn, the high expression of ISGs activates downstream anti-viral responses and subsequent inflammatory cytokine production by innate immune cells [@bib0031], like dendritic cells (DCs), macrophages, neutrophils, and monocytes. In the adaptive phase, diverse subsets of T cells and group 2 innate lymphoid cells regulate the discharge of secondary cytokines [@bib0030].Figure 1Representation of cytokine storm in the lung following severe SARS-CoV-2 infection. (A) SARS-CoV-2 land in nose, mouth and reach the lung. (B) Schematic of SARS-CoV-2 infecting lung epithelial cells. (C) Enlarge picture of the events in the production of the cytokine storm. (C1) Viruses infect lung epithelial cells and alveolar macrophages to produce progeny viruses and release cytokines and chemokines. (C2) Cytokine and/or chemokine activated macrophages, and virally infected dendritic cells lead to a more immense immune response and thus, initiate cytokine storm. (C3) Discharged chemokines draw additional inflammatory cells to migrate from blood vessels into the site of inflammation. These cells discharge additional chemokines or cytokines to amplify cytokine storm.Figure 1

Several anti-cytokine approaches have proven effective in reversing cytokine storm syndromes; including those triggered by viruses [@bib0032].These include drugs targeting interleukins including IL-1, IL-6, IL-18, and interferon-gamma. With respect to MSCs, Leng et al. has suggested using the cells specifically to combat the cytokine storm [@bib0007] in COVID19 patients. This approach is supported by data from non-viral acute lung injury animal studies. However, since existing animal models cannot replicate the natural course of acute lung injury [@bib0033], the aforementioned approach awaits further validation, especially in ARDS patients. A recent study by Park et al. demonstrated that nano-vesicles derived from MSCs ameliorates the signs of cytokine storm including weight and temperature changes as well as the excessive inflammatory response in a mouse model of sepsis provoked by bacterial outer membrane vesicles [@bib0034]. Similarly, Khatri et al. demonstrated that MSCs derived extracellular vesicles attenuate inflammation in an influenza virus-induced swine lung injury model [@bib0035]. Like-wise, MSCs isolated from human orbital fat tissues are effective in modulating LPS induced acute lung inflammation through paracrine regulation of macrophage-mediated cytokine-storm \[[@bib0036],[@bib0037]\].

Improving MSCs therapy for COVID19 patients {#sec0005}
===========================================

There is mounting interest in the development of protocols for the generation of optimized immunomodulatory MSCs, which could be customized to target specific viral diseases. Since most intravenously infused MSCs get trapped in the lung, cells can exert anti-inflammatory, anti-microbial and tissue repair functions while residing within the damaged lung via cell-to-cell contact without engrafting into the tissue [@bib0038]. However, the retention time of MSCs within the lung is extremely short [@bib0039], which may or may not be increased during injury or infection. Antonio et al. demonstrated that MSCs during their treatment to GvHD show therapeutic efficacy without engrafting into the tissue. The mechanism underpinning recovery was found to be immunosuppression exerted by apoptotic MSCs. The study showed that *in vivo* MSC undergo extensive apoptosis in response to the paracrine secretion by cytotoxic cells [@bib0019]. Worth mentioning, that beside the MSCs holding time in the tissue, the identification of the most clinically effective MSC subpopulation is of great importance to assure homogenous clinical outcomes. In this context, as suggested elsewhere in this paper, the present findings could be used as a biomarker to predict clinical responses to MSCs. Nevertheless, stem cells transplanted to the infected or diseased lung usually encounter massive cell death within a few days of therapy. To enhance engraftment, preconditioning of MSCs could be beneficial [@bib0040]. For example, exposure to hypoxia prolongs survival of engrafted MSCs and increases their effectiveness in treating bleomycin-induced lung injury in rodents [@bib0041]. Further, hypoxic preconditioning induces the expression of pro-survival and pro-angiogenic markers in MSCs [@bib0042]. Likewise, another study of similar nature reports that hypoxic- preconditioned-MSC efficiently enhances cell survival, engraftment, engrafted cell survival, improve pulmonary respiratory functions, downregulate inflammatory, and fibrotic factor expression in the bleomycin-induced pulmonary fibrosis mouse model [@bib0043]. Similarly, another important strategy is the genetic modification in MSCs to enhance their intrinsic ability to migrate and survive. For example, over-expression of CXCR4 facilitates MSCs homing and colonization within injured pulmonary tissues in acute lung injury [@bib0044], and MSCs engineered to overexpress HO-1 [@bib0045] or MnSOD [@bib0046] showed improved survival rate in models of lung injury. Keratinocyte Growth Factor gene transfected to MSCs improved lung infection and promote type II lung epithelial cell proliferation, thus, facilitating the survival of LPS induced ALI in a mouse model [@bib0047].

Other possible approaches to enhance the therapeutic effect of MSCs include over-expression of pro-reparative molecules including PDGF [@bib0048] and Ang-1 [@bib0049] or cytokines like IFN-γ [@bib0050], IL-10 [@bib0051] to increase their immuno-suppressive activity. Additionally, MSCs protect lung tissue from bleomycin induced injury [@bib0052] via expression of interleukin 1 receptor antagonist (IL1RN), as IL1RN can block the production and/or the activity of TNF-α and IL-1 [@bib0053]. Thus, identification of IL1RN expressing human MSCs subpopulations may provide a novel cellular vector for treating pulmonary infection in humans. Stimulation of MSCs with the pretreatment of pro-inflammatory signaling molecules (such as IL-1β) might also enhance the immunomodulatory property of MSCs by secreted exosomes [@bib0054].The latter represent a viable cell-free approach that can be used to treat infected individuals. MSCs also express high levels of toll-like receptor -3 (TLR3) and -4 (TLR4) [@bib0055]. The activation of TLR proteins represents an efficient mechanism to reinstate immune responses in the event of infection by hindering the immunosuppressive effect of MSCs [@bib0056]. Likewise, the activation of TLR on MSCs by pathogen-associated molecules like LPS is also effective [@bib0057]. Selections of MSCs based on expressed levels of immunomodulatory proteins may enhance efficacy. As an example, a subset of Stro-1^+^ MSCs showed enhance support for human hematopoietic stem cell engraftment and greater immunosuppressive capacity, while Stro-1^−^MSCs manifested a broad distribution after infusion into tissues \[[@bib0058],[@bib0059]\]. The ACE2 has broader allocations in humans [@bib0007], and possibly this may explain why some COVID19 patients present with multiple complications. In these cases, MSCs with the potential for broad *in vivo* distribution may be applied. Additionally, combination therapies may be explored to enhance the MSCs effect *in vivo*. For example, the combinational of the sphingosine 1 phosphate analog FTY720 and UCMSC attenuates acute lung injury and affords better survival in mice that each monotherapy [@bib0060]. Similarly, combining adipose-derived mesenchymal stem cells with pre-activated, disaggregated shape-changed platelets provides more protection to the rat lung from acute respiratory distress syndrome (ARDS) complicated by sepsis [@bib0061]. Nebulized Heparin along with MSCs inhibits coagulation and inflammatory pathways and modulates alveolar macrophages [@bib0062]. All the above-enlisted approaches seem advantageous, but whether they apply to COVID19 remains to be determined.

Discussion {#sec0006}
==========

The pandemic outbreak of COVID19 is rapidly spreading all over the world posing great health and economic challenges. So far available data suggest that the most vulnerable to infection are people age 65 or older and those with existing serious health issues [@bib0063]. In severely affected patients, lung inflammation is characterized by invasion of neutrophils and macrophages into the alveolar space, which together with over-activated pro-inflammatory cytokines results in impairment to the lung endothelial and epithelial [@bib0026]. In the absence of any specific therapies, the best way to manage COVID19 currently is to reduce the infection rate and mortality rate. Thus, there\'s a pressing need for the treatments that are effective in treating infection-induced cytokine storm, which is associated with increased mortality, but also prevent damage that may cause long-lasting impairment of lung function. Studies have shown that MSC-based therapies are effective in preventing steroid-resistant acute graft-versus-host disease (GvHD) and viral diseases [@bib0064]. The anti-viral [@bib0065] and anti-bacterial [@bib0066] action of MSCs combined with their hypoimmunogenic nature due to low MHC-I expression and lack of MHC-II expression is well documented. In context with citation numbers 64 and 65, ARDS develops most commonly in the setting of pneumonia (bacterial and viral; rarely fungal) [@bib0067]. In brief, the respiratory pathogens, such as respiratory viruses and bacteria, induce inflammation in pathologic lesions, and spread to lower respiratory cells along the respiratory tracts [@bib0068]. Interestingly, intact pathogens, e.g. influenza virus, have not been detected in patients with fatal outcomes or experimental animals with extensive pathologic lesions of ARDS \[[@bib0069],[@bib0070]\], indicating that the pathogens rather acting directly, secrets toxins into the host cells. Nearly all-infectious diseases, including pneumonia, may have a primary infection site where pathogens replicate, and where toxic substances are produced and released into nearby local lesions or systemic circulation. In the above lines, MSCs have shown the ability to control virus replication and the inflammatory response of the host in a relevant preclinical large animal model of influenza virus [@bib0035]. Similarly, in bacterial infections, the focus of a replication site may produce a lot of substances, including the bacteria, fragments of bacterial components, such as polysaccharide capsules and bacterial exotoxins, such as pneumolysin and bacteriocin, which could be detected by blood cultures and microscopic examination. In context with the above lines, MSC therapy in a sepsis murine model modulated transcription of up to 13% of the genome, with immune response-related effects including; a decrease in genes involved in antigen presentation and cell-to-cell interactions which regulates endothelial integrity, increased phagocytosis and bacterial killing [@bib0071], suggesting their anti-bacterial potential. MSCs also can transfer mitochondria and microvesicles that modulate immunity and epithelial response to injury [@bib0072]. These data, coupled with the fact that MSCs can be readily procured in large numbers from various tissue including adipose tissue, cord blood, liver, placenta and dental pulp [@bib0073] makes them an excellent candidate for cell therapy.

Accumulating evidence suggests that a subgroup of patients with severe COVID19 shows signs of cytokine storm syndrome [@bib0026]. The virally induced cytokine storm has been linked to uncontrolled pro-inflammatory responses that persuade significant pulmonary immunopathology. Thus, understanding the inter-relationship of the events between incubation and severe phases of the disease progression holds the key for therapeutic interventions. The plasma level of COVID19 patients showed a higher level of IL-6, IL-10, TNF-α, IL-2, IL-7, IL-10, GCSF, MCP-1, MIP-1α, and TNF-α [@bib0026], an indication of uncontrolled systematic cytokine storm, which was reportedly attenuated by treatment with MSCs [@bib0007] although the mechanism remains unclear. As in hyper-inflammation, the immunosuppressive measures are likely to be beneficial, thus, MSCs may exert effect through inhibiting the pro-inflammatory cytokines by the virtue of its immunosuppressive potential [@bib0007]. Further, by making direct cell-to-cell contact with immune cells or by secretion of a range of anti-inflammatory factors, MSCs can target immune cells and affect their function. Moreover, MSCs expresses several cell adhesion molecules like ICAM-1 and VCAM-1 to attract activated immune cells [@bib0074] thereby increasing their exposure to anti-inflammatory signals from MSCs. Further, IL-6 is a vital initiator of an uncontrolled cytokine storm [@bib0075], and is also a significant correlate in severe patients of COVID19 [@bib0076]. Previous studies indicated that MSCs have significantly inhibited cytokine storm by inhibiting the overproduction of the IL-6 [@bib0077]. Thus, it is reasonable to assume that to some extent MSCs may suppress the activated cytokines by suppressing the activation of IL-6 production. In any case, blocking IL-6 could also be an effective strategy. Licensing-approach is another robust technique to enhance the effectiveness of the MSCs. For example, the patients infected with SARS-CoV-2 has increased concentration of IFN-γ [@bib0026], and the activation IFN-γ prompts MSCs to exert their anti-inflammatory effect, which may be absent in severely affected COVID19 patients, as T cells are not well activated by SARS-CoV-2 infection [@bib0013]. In a recent clinical trial the Abu Dhabi Stem Cell Center (ADSCC), UAE has employed 'Activated' MSCs on 73 COVID19 patients, and the center claimed that inhaling of MSCs nebulized into a fine mist helped the patients to overcome the symptoms caused by the virus; though it did not kill the virus ([https://www.khaleejtimes.com/coronavirus-pandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it--](https://www.khaleejtimes.com/coronavirus-pandemic/coronavirus-uaes-stem-cell-treatment-fights-symptoms-of-covid-19-not-cure-it-){#interref0042}). Therefore, the study suggests that the use of licensing/priming/activating MSCs could be a potential therapeutic strategy against COVID19 [@bib0078].

MSCs have exhibited an improved lung function and endurance in chronic inflammatory lung diseases, including pulmonary hypertension, asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, and silicosis [@bib0079]. For instance, the COPD patients receiving bone marrow-derived MSCs experienced improved forced expiratory volume (NCT01306513) [@bib0080], and lung mechanics, besides the improved survival indicators (like low C-Reactive Protein and BODE index (for Body-mass index, airflow Obstruction, Dyspnea, and Exercise)(NCT01872624) [@bib0081]. Likewise, patients suffering from silicosis encounter increased lung perfusion suggesting that the cells were well tolerated in these patients (NCT01239862) [@bib0082]. These data cumulatively indicate the effectiveness and safety profile of MSCs in chronic lung diseases. Nevertheless, several reports have also documented the potential negative impact or no achievable benefit with MSCs transplantation in chronic pulmonary disease patients. For example, the multicenter, double-blind, placebo-controlled phase II clinical study by Weiss et al. employing non-HLA--matched allogeneic BM-MSCs, and showed no significant differences in the overall number of frequency of COPD exacerbations or disease severity (NCT00683722). However, no adverse reaction or deaths was noticed in patients under treatment [@bib0083]. Like chronic lung complications, MSCs have shown improvement in acute pulmonary anomalies too [@bib0084]. Several positive outcomes of MSC transplantation in acute lung diseases are well-documented \[[@bib0085],[@bib0086],[@bib0087]\]. For instance, a randomized phase II START trial showed the allogeneic MSCs treatment for moderate to severe ARDS resulted in no toxic effect in patients, as the study ended up with only one death out of the sixty patients who received the MSCs treatment. The death was judged to be unrelated [@bib0088]. However, a multicentre, open-label, dose-escalation, phase ISTem cells for ARDS Treatment (START) trial showed the adverse event in 3 patients out of 9 who received MSCs; two patients developed worsening multi-organ failure and shock on study day 6 and expired on study day 9 after the MSC infusion, and one showed multiple embolic infarcts of the spleen, kidneys, and brain. However, based on MRI results the embolic infarcts observed were believed to have occurred before the MSC infusion [@bib0089]. Although the safety of MSCs is well proved in lung pathologies, however, larger trials are needed to prove the effectiveness, and the issue related to an adverse event associated with it before it could be employed to acute or chronic settings of inflammatory lung diseases.

MSCs also have been shown to inhibit the differentiation of monocytes into dendritic cells (DCs), alter the cytokine profiles of DCs by upregulating regulatory cytokines and down-regulating pro-inflammatory cytokines, induce tolerant phenotypes of naive and effector T cells, and suppress T and NK cell differentiation and proliferation \[[@bib0015],[@bib0016],[@bib0017],[@bib0018]\] \[[Fig. 2](#fig0002){ref-type="fig"} \]. Interestingly, MSCs may also promote regulatory T-cell expansion and suppress proliferation of effector T-cells [@bib0090]. Moreover, the immunomodulation property of MSCs is linked to the expression of TLR receptors in MSCs, which is stimulated by pathogen-associated molecules like LPS or double-stranded RNA from viruses [@bib0091], such as SARS-CoV-2. Therefore, the role of TLR signaling in the abrogation of the disease by MSCs treatment cannot be ruled out. Altogether, the findings are consistent with evidence that MSCs enhance COVID19 resolution by inhibiting inflammatory responses.Figure 2A hypothetical sketch of the immune response of MSCs in the SARS-CoV-2 infected lung. SARS-CoV-2 infection to alveolus leads to uncontrolled production of growth factors. Depending on the cytokines signals MSCs initiate the immunoregulatory response and repair the pulmonary tissue. The potential therapeutic mechanisms offered by MSCs includes but not limited to immunomodulation, paracrine secretion, modulating cytokine storm, tissue protection, tissue repair and possibly viral resistance.Figure 2

One of the important measures in the COVID19 treatment is the time-window of the anti-inflammatory treatment, as severe patients usually underwent abrupt deterioration in 1--2 weeks after onset. Thus, prompt initiation of anti-inflammatory measures is likely to be of significant benefit. Therefore, identifying the correct timing and dose of MSCs, besides MSCs passage number, and route of delivery will be important to achieve favorable outcomes. Equally important may be determining the optimal tissue source of MSCs [@bib0092]. It is also important to take into account the fitness of MSCs, as freshly harvested cells may tend to show more robustness post-transplantation. Worth to mention, that at clinics the freshly harvested cells are the prime choice for infusion, although, cryopreserved cells are certainly becoming a norm nowadays. Since the clinical experiences of MSCs and SARS-CoV-2 viral infection in the lung is incredibly limited, further studies addressing the efficacy of MSCs in pulmonary damage are needed to reveal the true potential of MSC-based therapies for this viral infection.

Conclusion {#sec0007}
==========

MSCs therapy can overcome the present clinical challenges in the COVID19 patients especially those who are critically ill and are non-responsive to conventional therapies. The preliminary clinical data suggest that MSCs possess the capacity to lessen systemic inflammatory responses and protect against SARS-COV-2 virus-induced injury. Though preliminary results from clinical investigations are encouraging, it is too early to predict the therapeutic potential of MSCs in COVID19. Additional studies in a larger cohort of patients are needed to validate their potential efficacy.
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